Local regional immunotherapy of pleural tumours in rats

M. E. Ferrero, M. Corsi, E. Ferrero, C. Fortis, G. Gaja, C. Rugarli

Research output: Contribution to journalArticlepeer-review

Abstract

The effect of local immunotherapy with recombinant interleukin-2 (rIL-2) and lymphokineactivated killer (LAK) cells was studied on pleural tumours in rats. Growth of Yoshida AH-130 ascites hepatoma cells injected (250000 in 0.1 ml) into pleura of male inbred Fisher rats was evaluated at different times. Treatment with rIL-2 alone.(2 x 104CU/12h/rat) was given in rat pleura on the 4th day from transplantation until the 12th day. LAK cells were obtained on the 5th day from the spleen of rats who were treated for 2 days with 250000 CU/kg rIL-2 i.p. and then untreated. Treatment with rIL-2 at the same dose from the 4th to 8th day, plus LAK cells once a day from the 4th to 6th day at a dose of 2 to 4 x 106 cells in pleura, was also given. The results indicate that: (i) the use of rIL-2 alone induced a significant reduction in tumour cell growth; (ii) such a reduction was more evident when the treatment combined rIL-2 and 2 to 4 x 106 LAK cells, (iii) the use of rIL-2 plus 4 x 106 LAK cells significantly reduced pleural tumour cell growth with respect to the use of rIL-2 plus 2 x 106 and 3 x 106 LAK cells. The data show that the use of rIL-2 plus LAK cells locally against the experimental pleural tumours was an efficient immunotherapeutic method and that the present experimental model could be useful in the study of other immunotherapeutic treatments.

Original languageEnglish
Pages (from-to)57-63
Number of pages7
JournalInternational Journal of Immunotherapy
Volume11
Issue number2
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Local regional immunotherapy of pleural tumours in rats'. Together they form a unique fingerprint.

Cite this